RecruitingPhase 2Drug trialA Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisThis study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).